nodes	percent_of_prediction	percent_of_DWPC	metapath
Dorzolamide—CYP2C9—Teniposide—lymphatic system cancer	0.0705	0.35	CbGbCtD
Dorzolamide—CYP3A4—Cytarabine—lymphatic system cancer	0.0416	0.207	CbGbCtD
Dorzolamide—CYP3A4—Teniposide—lymphatic system cancer	0.041	0.203	CbGbCtD
Dorzolamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0287	0.142	CbGbCtD
Dorzolamide—CYP3A4—Vincristine—lymphatic system cancer	0.0197	0.0979	CbGbCtD
Dorzolamide—Confusional state—Fludarabine—lymphatic system cancer	0.00273	0.00341	CcSEcCtD
Dorzolamide—Dysuria—Vincristine—lymphatic system cancer	0.00272	0.0034	CcSEcCtD
Dorzolamide—Depression—Carmustine—lymphatic system cancer	0.00271	0.00339	CcSEcCtD
Dorzolamide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0027	0.00339	CcSEcCtD
Dorzolamide—Oedema—Fludarabine—lymphatic system cancer	0.0027	0.00339	CcSEcCtD
Dorzolamide—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00268	0.00335	CcSEcCtD
Dorzolamide—Decreased appetite—Teniposide—lymphatic system cancer	0.00267	0.00335	CcSEcCtD
Dorzolamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00265	0.00332	CcSEcCtD
Dorzolamide—Urinary tract infection—Carmustine—lymphatic system cancer	0.00264	0.0033	CcSEcCtD
Dorzolamide—Rash—Mechlorethamine—lymphatic system cancer	0.00263	0.00329	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00263	0.00329	CcSEcCtD
Dorzolamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00263	0.00329	CcSEcCtD
Dorzolamide—Weight decreased—Vincristine—lymphatic system cancer	0.00263	0.00329	CcSEcCtD
Dorzolamide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00261	0.00327	CcSEcCtD
Dorzolamide—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00261	0.00326	CcSEcCtD
Dorzolamide—Depression—Vincristine—lymphatic system cancer	0.00258	0.00323	CcSEcCtD
Dorzolamide—Anorexia—Fludarabine—lymphatic system cancer	0.00258	0.00323	CcSEcCtD
Dorzolamide—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00256	0.00321	CcSEcCtD
Dorzolamide—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00255	0.0032	CcSEcCtD
Dorzolamide—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00255	0.0032	CcSEcCtD
Dorzolamide—Myocardial infarction—Vincristine—lymphatic system cancer	0.00254	0.00318	CcSEcCtD
Dorzolamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00253	0.00317	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00252	0.00315	CcSEcCtD
Dorzolamide—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00249	0.00311	CcSEcCtD
Dorzolamide—Sweating—Vincristine—lymphatic system cancer	0.00248	0.00311	CcSEcCtD
Dorzolamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00248	0.0031	CcSEcCtD
Dorzolamide—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00247	0.0031	CcSEcCtD
Dorzolamide—Alopecia—Bleomycin—lymphatic system cancer	0.00247	0.00309	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00246	0.00308	CcSEcCtD
Dorzolamide—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00245	0.00307	CcSEcCtD
Dorzolamide—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00245	0.00307	CcSEcCtD
Dorzolamide—Urticaria—Teniposide—lymphatic system cancer	0.00244	0.00306	CcSEcCtD
Dorzolamide—Abdominal pain—Teniposide—lymphatic system cancer	0.00243	0.00305	CcSEcCtD
Dorzolamide—Body temperature increased—Teniposide—lymphatic system cancer	0.00243	0.00305	CcSEcCtD
Dorzolamide—Erythema—Bleomycin—lymphatic system cancer	0.00243	0.00304	CcSEcCtD
Dorzolamide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00243	0.00304	CcSEcCtD
Dorzolamide—Hallucination—Carmustine—lymphatic system cancer	0.00242	0.00303	CcSEcCtD
Dorzolamide—Sweating—Mitoxantrone—lymphatic system cancer	0.00242	0.00303	CcSEcCtD
Dorzolamide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00241	0.00302	CcSEcCtD
Dorzolamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00238	0.00298	CcSEcCtD
Dorzolamide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00237	0.00296	CcSEcCtD
Dorzolamide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00235	0.00295	CcSEcCtD
Dorzolamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00235	0.00294	CcSEcCtD
Dorzolamide—Visual impairment—Carmustine—lymphatic system cancer	0.00235	0.00294	CcSEcCtD
Dorzolamide—Fatigue—Fludarabine—lymphatic system cancer	0.00233	0.00292	CcSEcCtD
Dorzolamide—Hallucination—Vincristine—lymphatic system cancer	0.00231	0.0029	CcSEcCtD
Dorzolamide—Pain—Fludarabine—lymphatic system cancer	0.00231	0.0029	CcSEcCtD
Dorzolamide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00231	0.00289	CcSEcCtD
Dorzolamide—Respiratory failure—Methotrexate—lymphatic system cancer	0.00229	0.00286	CcSEcCtD
Dorzolamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00227	0.00284	CcSEcCtD
Dorzolamide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00225	0.00281	CcSEcCtD
Dorzolamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00223	0.00279	CcSEcCtD
Dorzolamide—Asthenia—Teniposide—lymphatic system cancer	0.00221	0.00276	CcSEcCtD
Dorzolamide—Pruritus—Teniposide—lymphatic system cancer	0.00218	0.00273	CcSEcCtD
Dorzolamide—Arrhythmia—Carmustine—lymphatic system cancer	0.00218	0.00272	CcSEcCtD
Dorzolamide—Alopecia—Carmustine—lymphatic system cancer	0.00215	0.0027	CcSEcCtD
Dorzolamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00214	0.00268	CcSEcCtD
Dorzolamide—Erythema—Carmustine—lymphatic system cancer	0.00212	0.00266	CcSEcCtD
Dorzolamide—Cough—Bleomycin—lymphatic system cancer	0.00212	0.00265	CcSEcCtD
Dorzolamide—Diarrhoea—Teniposide—lymphatic system cancer	0.0021	0.00264	CcSEcCtD
Dorzolamide—Chest pain—Bleomycin—lymphatic system cancer	0.00207	0.00259	CcSEcCtD
Dorzolamide—Alopecia—Vincristine—lymphatic system cancer	0.00205	0.00257	CcSEcCtD
Dorzolamide—Back pain—Carmustine—lymphatic system cancer	0.00205	0.00257	CcSEcCtD
Dorzolamide—Discomfort—Bleomycin—lymphatic system cancer	0.00204	0.00256	CcSEcCtD
Dorzolamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00202	0.00253	CcSEcCtD
Dorzolamide—Alopecia—Mitoxantrone—lymphatic system cancer	0.002	0.00251	CcSEcCtD
Dorzolamide—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.002	0.0025	CcSEcCtD
Dorzolamide—Confusional state—Bleomycin—lymphatic system cancer	0.002	0.0025	CcSEcCtD
Dorzolamide—Vision blurred—Carmustine—lymphatic system cancer	0.002	0.0025	CcSEcCtD
Dorzolamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00199	0.00249	CcSEcCtD
Dorzolamide—Oedema—Bleomycin—lymphatic system cancer	0.00198	0.00248	CcSEcCtD
Dorzolamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00198	0.00248	CcSEcCtD
Dorzolamide—Erythema—Mitoxantrone—lymphatic system cancer	0.00197	0.00247	CcSEcCtD
Dorzolamide—Back pain—Vincristine—lymphatic system cancer	0.00196	0.00245	CcSEcCtD
Dorzolamide—Vomiting—Teniposide—lymphatic system cancer	0.00196	0.00245	CcSEcCtD
Dorzolamide—Asthenia—Fludarabine—lymphatic system cancer	0.00194	0.00243	CcSEcCtD
Dorzolamide—Rash—Teniposide—lymphatic system cancer	0.00194	0.00243	CcSEcCtD
Dorzolamide—Dermatitis—Teniposide—lymphatic system cancer	0.00194	0.00243	CcSEcCtD
Dorzolamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00193	0.00242	CcSEcCtD
Dorzolamide—Headache—Teniposide—lymphatic system cancer	0.00193	0.00241	CcSEcCtD
Dorzolamide—Pruritus—Fludarabine—lymphatic system cancer	0.00191	0.0024	CcSEcCtD
Dorzolamide—Back pain—Mitoxantrone—lymphatic system cancer	0.00191	0.00239	CcSEcCtD
Dorzolamide—Anorexia—Bleomycin—lymphatic system cancer	0.00189	0.00237	CcSEcCtD
Dorzolamide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00186	0.00233	CcSEcCtD
Dorzolamide—Hypotension—Bleomycin—lymphatic system cancer	0.00185	0.00232	CcSEcCtD
Dorzolamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00185	0.00232	CcSEcCtD
Dorzolamide—Hypertension—Carmustine—lymphatic system cancer	0.00183	0.00229	CcSEcCtD
Dorzolamide—Nausea—Teniposide—lymphatic system cancer	0.00183	0.00229	CcSEcCtD
Dorzolamide—Vertigo—Vincristine—lymphatic system cancer	0.00182	0.00228	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00181	0.00226	CcSEcCtD
Dorzolamide—Chest pain—Carmustine—lymphatic system cancer	0.0018	0.00226	CcSEcCtD
Dorzolamide—Anxiety—Carmustine—lymphatic system cancer	0.0018	0.00225	CcSEcCtD
Dorzolamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00178	0.00223	CcSEcCtD
Dorzolamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00177	0.00221	CcSEcCtD
Dorzolamide—Hypertension—Vincristine—lymphatic system cancer	0.00175	0.00219	CcSEcCtD
Dorzolamide—Confusional state—Carmustine—lymphatic system cancer	0.00174	0.00218	CcSEcCtD
Dorzolamide—Oedema—Carmustine—lymphatic system cancer	0.00173	0.00217	CcSEcCtD
Dorzolamide—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00173	0.00216	CcSEcCtD
Dorzolamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00172	0.00216	CcSEcCtD
Dorzolamide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00172	0.00215	CcSEcCtD
Dorzolamide—Cough—Mitoxantrone—lymphatic system cancer	0.00172	0.00215	CcSEcCtD
Dorzolamide—Vomiting—Fludarabine—lymphatic system cancer	0.00172	0.00215	CcSEcCtD
Dorzolamide—Rash—Fludarabine—lymphatic system cancer	0.0017	0.00213	CcSEcCtD
Dorzolamide—Dermatitis—Fludarabine—lymphatic system cancer	0.0017	0.00213	CcSEcCtD
Dorzolamide—Hypertension—Mitoxantrone—lymphatic system cancer	0.0017	0.00213	CcSEcCtD
Dorzolamide—Pain—Bleomycin—lymphatic system cancer	0.0017	0.00212	CcSEcCtD
Dorzolamide—Headache—Fludarabine—lymphatic system cancer	0.00169	0.00212	CcSEcCtD
Dorzolamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00168	0.0021	CcSEcCtD
Dorzolamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00168	0.0021	CcSEcCtD
Dorzolamide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00167	0.00209	CcSEcCtD
Dorzolamide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00166	0.00208	CcSEcCtD
Dorzolamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00166	0.00208	CcSEcCtD
Dorzolamide—Oedema—Vincristine—lymphatic system cancer	0.00165	0.00207	CcSEcCtD
Dorzolamide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00165	0.00207	CcSEcCtD
Dorzolamide—Anorexia—Carmustine—lymphatic system cancer	0.00165	0.00207	CcSEcCtD
Dorzolamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00163	0.00205	CcSEcCtD
Dorzolamide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00162	0.00203	CcSEcCtD
Dorzolamide—Hypotension—Carmustine—lymphatic system cancer	0.00162	0.00202	CcSEcCtD
Dorzolamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00161	0.00201	CcSEcCtD
Dorzolamide—Oedema—Mitoxantrone—lymphatic system cancer	0.00161	0.00201	CcSEcCtD
Dorzolamide—Nausea—Fludarabine—lymphatic system cancer	0.00161	0.00201	CcSEcCtD
Dorzolamide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0016	0.002	CcSEcCtD
Dorzolamide—Shock—Mitoxantrone—lymphatic system cancer	0.00158	0.00198	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00158	0.00197	CcSEcCtD
Dorzolamide—Urticaria—Bleomycin—lymphatic system cancer	0.00157	0.00197	CcSEcCtD
Dorzolamide—Anorexia—Vincristine—lymphatic system cancer	0.00157	0.00197	CcSEcCtD
Dorzolamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00157	0.00196	CcSEcCtD
Dorzolamide—Insomnia—Carmustine—lymphatic system cancer	0.00157	0.00196	CcSEcCtD
Dorzolamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00156	0.00195	CcSEcCtD
Dorzolamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00155	0.00195	CcSEcCtD
Dorzolamide—Mood swings—Methotrexate—lymphatic system cancer	0.00154	0.00193	CcSEcCtD
Dorzolamide—Hypotension—Vincristine—lymphatic system cancer	0.00154	0.00193	CcSEcCtD
Dorzolamide—Dyspnoea—Carmustine—lymphatic system cancer	0.00154	0.00193	CcSEcCtD
Dorzolamide—Somnolence—Carmustine—lymphatic system cancer	0.00154	0.00193	CcSEcCtD
Dorzolamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00153	0.00192	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0015	0.00188	CcSEcCtD
Dorzolamide—Decreased appetite—Carmustine—lymphatic system cancer	0.0015	0.00188	CcSEcCtD
Dorzolamide—Hypotension—Mitoxantrone—lymphatic system cancer	0.0015	0.00188	CcSEcCtD
Dorzolamide—Insomnia—Vincristine—lymphatic system cancer	0.00149	0.00187	CcSEcCtD
Dorzolamide—Paraesthesia—Vincristine—lymphatic system cancer	0.00148	0.00186	CcSEcCtD
Dorzolamide—Pain—Carmustine—lymphatic system cancer	0.00148	0.00185	CcSEcCtD
Dorzolamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00147	0.00184	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00147	0.00184	CcSEcCtD
Dorzolamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00146	0.00183	CcSEcCtD
Dorzolamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00144	0.00181	CcSEcCtD
Dorzolamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00144	0.0018	CcSEcCtD
Dorzolamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00143	0.0018	CcSEcCtD
Dorzolamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00143	0.00179	CcSEcCtD
Dorzolamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00143	0.00179	CcSEcCtD
Dorzolamide—Fatigue—Vincristine—lymphatic system cancer	0.00142	0.00178	CcSEcCtD
Dorzolamide—Asthenia—Bleomycin—lymphatic system cancer	0.00142	0.00178	CcSEcCtD
Dorzolamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00142	0.00177	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00141	0.00177	CcSEcCtD
Dorzolamide—Pain—Vincristine—lymphatic system cancer	0.00141	0.00177	CcSEcCtD
Dorzolamide—Pruritus—Bleomycin—lymphatic system cancer	0.0014	0.00176	CcSEcCtD
Dorzolamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0014	0.00175	CcSEcCtD
Dorzolamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00139	0.00174	CcSEcCtD
Dorzolamide—Pain—Mitoxantrone—lymphatic system cancer	0.00138	0.00172	CcSEcCtD
Dorzolamide—Abdominal pain—Carmustine—lymphatic system cancer	0.00137	0.00171	CcSEcCtD
Dorzolamide—Body temperature increased—Carmustine—lymphatic system cancer	0.00137	0.00171	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00135	0.00169	CcSEcCtD
Dorzolamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00133	0.00166	CcSEcCtD
Dorzolamide—Dysuria—Methotrexate—lymphatic system cancer	0.00132	0.00165	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00132	0.00165	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00131	0.00164	CcSEcCtD
Dorzolamide—Body temperature increased—Vincristine—lymphatic system cancer	0.00131	0.00164	CcSEcCtD
Dorzolamide—Abdominal pain—Vincristine—lymphatic system cancer	0.00131	0.00164	CcSEcCtD
Dorzolamide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.0013	0.00163	CcSEcCtD
Dorzolamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00128	0.0016	CcSEcCtD
Dorzolamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00127	0.0016	CcSEcCtD
Dorzolamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00127	0.00159	CcSEcCtD
Dorzolamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00127	0.00159	CcSEcCtD
Dorzolamide—Vomiting—Bleomycin—lymphatic system cancer	0.00126	0.00158	CcSEcCtD
Dorzolamide—Depression—Methotrexate—lymphatic system cancer	0.00125	0.00157	CcSEcCtD
Dorzolamide—Rash—Bleomycin—lymphatic system cancer	0.00125	0.00157	CcSEcCtD
Dorzolamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00125	0.00156	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00125	0.00156	CcSEcCtD
Dorzolamide—Asthenia—Carmustine—lymphatic system cancer	0.00124	0.00155	CcSEcCtD
Dorzolamide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00122	0.00153	CcSEcCtD
Dorzolamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00122	0.00152	CcSEcCtD
Dorzolamide—Sweating—Methotrexate—lymphatic system cancer	0.0012	0.00151	CcSEcCtD
Dorzolamide—Epistaxis—Methotrexate—lymphatic system cancer	0.00119	0.00148	CcSEcCtD
Dorzolamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00119	0.00148	CcSEcCtD
Dorzolamide—Asthenia—Vincristine—lymphatic system cancer	0.00119	0.00148	CcSEcCtD
Dorzolamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00118	0.00148	CcSEcCtD
Dorzolamide—Nausea—Bleomycin—lymphatic system cancer	0.00118	0.00147	CcSEcCtD
Dorzolamide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00117	0.00147	CcSEcCtD
Dorzolamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00115	0.00145	CcSEcCtD
Dorzolamide—Dizziness—Carmustine—lymphatic system cancer	0.00114	0.00143	CcSEcCtD
Dorzolamide—Diarrhoea—Vincristine—lymphatic system cancer	0.00113	0.00142	CcSEcCtD
Dorzolamide—Pharyngitis—Methotrexate—lymphatic system cancer	0.00112	0.0014	CcSEcCtD
Dorzolamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0011	0.00138	CcSEcCtD
Dorzolamide—Vomiting—Carmustine—lymphatic system cancer	0.0011	0.00138	CcSEcCtD
Dorzolamide—Dizziness—Vincristine—lymphatic system cancer	0.00109	0.00137	CcSEcCtD
Dorzolamide—Rash—Carmustine—lymphatic system cancer	0.00109	0.00137	CcSEcCtD
Dorzolamide—Dermatitis—Carmustine—lymphatic system cancer	0.00109	0.00137	CcSEcCtD
Dorzolamide—Visual impairment—Methotrexate—lymphatic system cancer	0.00109	0.00136	CcSEcCtD
Dorzolamide—Headache—Carmustine—lymphatic system cancer	0.00108	0.00136	CcSEcCtD
Dorzolamide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00107	0.00134	CcSEcCtD
Dorzolamide—Tinnitus—Methotrexate—lymphatic system cancer	0.00105	0.00132	CcSEcCtD
Dorzolamide—Vomiting—Vincristine—lymphatic system cancer	0.00105	0.00132	CcSEcCtD
Dorzolamide—Rash—Vincristine—lymphatic system cancer	0.00104	0.0013	CcSEcCtD
Dorzolamide—Dermatitis—Vincristine—lymphatic system cancer	0.00104	0.0013	CcSEcCtD
Dorzolamide—Headache—Vincristine—lymphatic system cancer	0.00103	0.0013	CcSEcCtD
Dorzolamide—Nausea—Carmustine—lymphatic system cancer	0.00103	0.00129	CcSEcCtD
Dorzolamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00102	0.00128	CcSEcCtD
Dorzolamide—Rash—Mitoxantrone—lymphatic system cancer	0.00101	0.00127	CcSEcCtD
Dorzolamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00101	0.00127	CcSEcCtD
Dorzolamide—Headache—Mitoxantrone—lymphatic system cancer	0.00101	0.00126	CcSEcCtD
Dorzolamide—Alopecia—Methotrexate—lymphatic system cancer	0.000997	0.00125	CcSEcCtD
Dorzolamide—Erythema—Methotrexate—lymphatic system cancer	0.000982	0.00123	CcSEcCtD
Dorzolamide—Nausea—Vincristine—lymphatic system cancer	0.000981	0.00123	CcSEcCtD
Dorzolamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000962	0.0012	CcSEcCtD
Dorzolamide—Nausea—Mitoxantrone—lymphatic system cancer	0.000956	0.0012	CcSEcCtD
Dorzolamide—Back pain—Methotrexate—lymphatic system cancer	0.00095	0.00119	CcSEcCtD
Dorzolamide—Vision blurred—Methotrexate—lymphatic system cancer	0.000925	0.00116	CcSEcCtD
Dorzolamide—Vertigo—Methotrexate—lymphatic system cancer	0.000882	0.0011	CcSEcCtD
Dorzolamide—Cough—Methotrexate—lymphatic system cancer	0.000857	0.00107	CcSEcCtD
Dorzolamide—Arthralgia—Methotrexate—lymphatic system cancer	0.000836	0.00105	CcSEcCtD
Dorzolamide—Chest pain—Methotrexate—lymphatic system cancer	0.000836	0.00105	CcSEcCtD
Dorzolamide—Discomfort—Methotrexate—lymphatic system cancer	0.000826	0.00103	CcSEcCtD
Dorzolamide—Confusional state—Methotrexate—lymphatic system cancer	0.000808	0.00101	CcSEcCtD
Dorzolamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000801	0.001	CcSEcCtD
Dorzolamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000775	0.00097	CcSEcCtD
Dorzolamide—Anorexia—Methotrexate—lymphatic system cancer	0.000764	0.000957	CcSEcCtD
Dorzolamide—Hypotension—Methotrexate—lymphatic system cancer	0.000749	0.000938	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00073	0.000914	CcSEcCtD
Dorzolamide—Insomnia—Methotrexate—lymphatic system cancer	0.000725	0.000908	CcSEcCtD
Dorzolamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00072	0.000901	CcSEcCtD
Dorzolamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000715	0.000895	CcSEcCtD
Dorzolamide—Somnolence—Methotrexate—lymphatic system cancer	0.000713	0.000892	CcSEcCtD
Dorzolamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000705	0.000884	CcSEcCtD
Dorzolamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000697	0.000873	CcSEcCtD
Dorzolamide—Fatigue—Methotrexate—lymphatic system cancer	0.000691	0.000865	CcSEcCtD
Dorzolamide—Pain—Methotrexate—lymphatic system cancer	0.000685	0.000858	CcSEcCtD
Dorzolamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00066	0.000827	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000655	0.000821	CcSEcCtD
Dorzolamide—Urticaria—Methotrexate—lymphatic system cancer	0.000637	0.000797	CcSEcCtD
Dorzolamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000634	0.000793	CcSEcCtD
Dorzolamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000634	0.000793	CcSEcCtD
Dorzolamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00059	0.000739	CcSEcCtD
Dorzolamide—Asthenia—Methotrexate—lymphatic system cancer	0.000575	0.00072	CcSEcCtD
Dorzolamide—Pruritus—Methotrexate—lymphatic system cancer	0.000567	0.00071	CcSEcCtD
Dorzolamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000548	0.000687	CcSEcCtD
Dorzolamide—Dizziness—Methotrexate—lymphatic system cancer	0.00053	0.000664	CcSEcCtD
Dorzolamide—Vomiting—Methotrexate—lymphatic system cancer	0.00051	0.000638	CcSEcCtD
Dorzolamide—Rash—Methotrexate—lymphatic system cancer	0.000505	0.000633	CcSEcCtD
Dorzolamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000505	0.000632	CcSEcCtD
Dorzolamide—Headache—Methotrexate—lymphatic system cancer	0.000502	0.000629	CcSEcCtD
Dorzolamide—Nausea—Methotrexate—lymphatic system cancer	0.000476	0.000596	CcSEcCtD
